Epidemiology, virology, clinical features, diagnosis, and treatment of SARS-CoV-2 infection

(2021) Epidemiology, virology, clinical features, diagnosis, and treatment of SARS-CoV-2 infection. Journal of Experimental and Clinical Medicine (Turkey). pp. 649-668. ISSN 13094483 (ISSN)

Full text not available from this repository.

Abstract

Since December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged and spread quickly worldwide. The disease is generally mild in adult people but in any with comorbidities may proceed to acute respiratory distress syndrome (ARDS), pneumonia, and multi-organ dysfunction. By performing molecular tests on respiratory secretions can diagnose the virus. Elevated C-reactive protein (CRP) and normal/low white cell counts are common laboratory diagnoses of COVID-19 while the tomographic chest scan is usually irregular for many infected people. Some patients progress to respiratory failure, pneumonia, and finally death by the end of the first week of illness because of the sharp rise in inflammatory cytokines such as IL7, IL2, GCSF, IL10, MIP1A, MCP1, IP10, and TNFα. Various approaches to the COVID- 19 are being performed by scientists. Use of chemical medical drugs that are effective for other viral infections. Among them, remdesivir was approved by FDA on 1th May 2020 because of its impact to treat patients. Also, several studies have revealed that many Chinese herbal remedies have a remarkable impact on the healing process when simultaneously were used along with pharmacological drugs. In the meantime, many efforts have been made to produce an effective vaccine, and so far, the Ad5-vectored COVID-19 vaccine has been successful and has entered phase 2 in the human trial. The current review focus on epidemiology, virology, clinical features, diagnosis, and available treatment of coronavirus that might assist researchers and clinicians in establishing action options for timely against this infection. © 2021 Ondokuz Mayis Universitesi. All rights reserved.

Item Type: Article
Keywords: Coronavirus COVID-19 SARS-CoV-2 Severe acute respiratory syndrome Treatment aciclovir anakinra anti-SARS-CoV-2 agent atazanavir azithromycin baloxavir baricitinib bevacizumab brilacidin bromhexine C reactive protein chloroquine colchicine convalescent plasma danoprevir darunavir disulfiram eculizumab favipiravir fingolimod galidesivir ganciclovir granulocyte colony stimulating factor receptor griffithsin hydroxychloroquine interferon interleukin 10 interleukin 2 interleukin 7 nafamstat nelfinavir nitazoxanide oseltamivir pirfenidone remdesivir SARS-CoV-2 vaccine teicoplanin thalidomide tumor necrosis factor umifenovir adult respiratory distress syndrome antiviral therapy clinical feature convalescent plasma therapy coronavirus disease 2019 drug therapy human mesenchymal stem cell nonhuman pathogenesis pneumonia respiratory failure Review virology
Page Range: pp. 649-668
Journal or Publication Title: Journal of Experimental and Clinical Medicine (Turkey)
Journal Index: Scopus
Volume: 38
Number: 4
Identification Number: https://doi.org/10.52142/OMUJECM.38.4.44
ISSN: 13094483 (ISSN)
Depositing User: Zahra Otroj
URI: http://eprints.mui.ac.ir/id/eprint/18103

Actions (login required)

View Item View Item